APA (7th ed.) Citation

Roeper, J., Christopoulos, P., Falk, M., Heukamp, L., Tiemann, M., Stenzinger, A., . . . Griesinger, F. (2022). TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy: EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Translational Lung Cancer Research, 11(1), . https://doi.org/10.21037/tlcr-21-754

Chicago Style (17th ed.) Citation

Roeper, Julia, Petros Christopoulos, Markus Falk, Lukas Heukamp, Markus Tiemann, Albrecht Stenzinger, Michael Thomas, and Frank Griesinger. "TP53 Co-mutations as an Independent Prognostic Factor in 2nd and Further Line Therapy: EGFR Mutated Non-small Cell Lung Cancer IV Patients Treated with Osimertinib." Translational Lung Cancer Research 11, no. 1 (2022). https://doi.org/10.21037/tlcr-21-754.

MLA (9th ed.) Citation

Roeper, Julia, et al. "TP53 Co-mutations as an Independent Prognostic Factor in 2nd and Further Line Therapy: EGFR Mutated Non-small Cell Lung Cancer IV Patients Treated with Osimertinib." Translational Lung Cancer Research, vol. 11, no. 1, 2022, https://doi.org/10.21037/tlcr-21-754.